

Table 35. Completion of Tuberculosis Therapy (COT): 59 Reporting Areas, 1998

Reporting Area	Total	Therapy \leq 1 Year Indicated ¹			Therapy >1 Year Indicated ²		Overall	
	Cases	No. ³	COT \leq 1 Year(%)	COT(%)	No. ³	COT(%)	No. ³	COT(%)
United States	18,295	15,807	79.1	90.7	224	71.0	16,031	90.4
Alabama	381	330	83.9	93.9	3	100.0	333	94.0
Alaska	55	54	85.2	90.7	0	...	54	90.7
Arizona	254	211	84.4	95.7	5	80.0	216	95.4
Arkansas	171	140	85.0	93.6	0	...	140	93.6
California	3,851	3,402	78.8	92.2	55	85.5	3,457	92.0
Colorado	79	64	96.9	96.9	1	100.0	65	96.9
Connecticut	127	109	82.6	89.0	2	100.0	111	89.2
Delaware	36	29	75.9	93.1	0	...	29	93.1
District of Columbia	107	90	73.3	85.6	4	100.0	94	86.2
Florida	1,295	1,098	81.4	93.7	15	73.3	1,113	93.4
Georgia	630	556	79.9	90.6	4	75.0	560	90.5
Hawaii	181	155	84.5	92.3	0	...	155	92.3
Idaho	14	14	64.3	85.7	0	...	14	85.7
Illinois	842	722	78.3	89.3	12	75.0	734	89.1
Indiana	188	154	83.1	94.8	3	66.7	157	94.3
Iowa	55	44	75.0	95.5	0	...	44	95.5
Kansas	56	49	93.9	100.0	1	100.0	50	100.0
Kentucky	179	146	80.1	90.4	1	100.0	147	90.5
Louisiana	379	333	--	--	3	--	336	--
Maine	13	10	70.0	100.0	0	...	10	100.0
Maryland	324	278	85.3	94.2	5	60.0	283	93.6
Massachusetts	280	252	81.7	92.9	1	100.0	253	92.9
Michigan	383	323	84.2	92.3	5	60.0	328	91.8
Minnesota	161	146	82.2	93.2	2	100.0	148	93.2
Mississippi	225	198	89.9	97.5	1	100.0	199	97.5
Missouri	184	150	77.3	87.3	1	100.0	151	87.4
Montana	20	14	100.0	100.0	0	...	14	100.0
Nebraska	31	26	69.2	76.9	2	100.0	28	78.6
Nevada	128	114	83.3	91.2	1	100.0	115	91.3
New Hampshire	14	13	100.0	100.0	0	...	13	100.0
New Jersey	639	546	74.4	91.2	12	91.7	558	91.2
New Mexico	68	58	87.9	98.3	1	100.0	59	98.3
New York State ⁴	438	384	70.6	85.4	4	50.0	388	85.1
New York City	1,537	1,313	80.7	90.4	35	25.7	1,348	88.7
North Carolina	498	424	91.7	98.3	4	75.0	428	98.1
North Dakota	10	8	62.5	100.0	1	100.0	9	100.0
Ohio	230	194	77.3	91.8	4	75.0	198	91.4
Oklahoma	198	168	78.6	88.7	1	0.0	169	88.2
Oregon	156	138	77.5	85.5	3	66.7	141	85.1
Pennsylvania	448	382	--	--	4	--	386	--
Rhode Island	63	58	82.8	96.6	1	100.0	59	96.6
South Carolina	286	240	74.2	93.8	0	...	240	93.8
South Dakota	23	13	92.3	100.0	0	...	13	100.0
Tennessee	439	372	81.5	94.9	4	100.0	376	94.9
Texas	1,803	1,571	77.3	89.4	19	63.2	1,590	89.1
Utah	52	48	75.0	95.8	0	...	48	95.8
Vermont	5	4	100.0	100.0	0	...	4	100.0
Virginia	339	303	83.5	92.4	2	100.0	305	92.5
Washington	265	235	84.3	94.0	2	50.0	237	93.7
West Virginia	42	30	66.7	83.3	0	...	30	83.3
Wisconsin	109	90	83.3	96.7	0	...	90	96.7
Wyoming	4	4	100.0	100.0	0	...	4	100.0
American Samoa ⁵
Fed. States of Micronesia ⁵
Guam ⁵	89	83	88.0	89.2	1	0.0	84	88.1
N. Mariana Islands ⁵	110	107	79.4	80.4	1	0.0	108	79.6
Puerto Rico ⁵	201	150	80.7	91.3	4	75.0	154	90.9
Republic of Palau ⁵
U.S. Virgin Islands ⁵

1. Initial isolate susceptible to rifampin (n=12,118) or susceptibility unknown (n=316); culture-negative (n=2,562); culture status unknown (n=811); age unknown (n=0).
2. Initial isolate rifampin resistant, or pediatric (aged <15) case with meningeal, bone or joint, or miliary disease.
3. Number of cases in persons alive at diagnosis, with initial drug regimen of one or more drugs prescribed, who did not die during therapy. Percentage for U.S. based on 52 reporting areas (50 states, New York City, and the District of Columbia). Percentages shown only for reporting areas with information on reason therapy stopped for >90% of cases.
4. Excludes New York City.
5. Not included in U.S. totals.

Ellipses indicate data not available.

Note: See Technical Notes (Appendix A) for description of COT calculation.